Algert Global LLC Purchases 770 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Algert Global LLC increased its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 54.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,180 shares of the biotechnology company’s stock after acquiring an additional 770 shares during the quarter. Algert Global LLC’s holdings in Ascendis Pharma A/S were worth $297,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. GSA Capital Partners LLP purchased a new stake in shares of Ascendis Pharma A/S during the 1st quarter valued at $992,000. Price T Rowe Associates Inc. MD raised its stake in Ascendis Pharma A/S by 23.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock valued at $269,374,000 after buying an additional 336,976 shares during the last quarter. ADAR1 Capital Management LLC acquired a new stake in Ascendis Pharma A/S in the fourth quarter worth about $5,779,000. Perceptive Advisors LLC acquired a new position in shares of Ascendis Pharma A/S during the fourth quarter valued at about $16,648,000. Finally, BNP Paribas Financial Markets raised its position in shares of Ascendis Pharma A/S by 4,231.4% in the 1st quarter. BNP Paribas Financial Markets now owns 75,540 shares of the biotechnology company’s stock valued at $11,419,000 after purchasing an additional 73,796 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ASND. TD Cowen dropped their target price on shares of Ascendis Pharma A/S from $175.00 to $157.00 and set a “buy” rating on the stock in a research report on Wednesday, September 4th. Jefferies Financial Group upped their target price on Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a “buy” rating in a research report on Tuesday, August 13th. Citigroup lifted their price target on Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th. StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Thursday, September 5th. Finally, Wells Fargo & Company upped their target price on Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $195.00.

Ascendis Pharma A/S Stock Performance

Shares of Ascendis Pharma A/S stock opened at $132.05 on Wednesday. Ascendis Pharma A/S has a fifty-two week low of $85.29 and a fifty-two week high of $161.00. The company has a market cap of $7.69 billion, a P/E ratio of -13.74 and a beta of 0.64. The firm has a 50-day simple moving average of $135.50 and a two-hundred day simple moving average of $136.15.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The business had revenue of $38.75 million for the quarter, compared to analysts’ expectations of $94.74 million. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 154.18%. Equities research analysts forecast that Ascendis Pharma A/S will post -7.15 EPS for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.